9 Best Rising Penny Stocks to Buy According to Wall Street Analysts
On June 27, Jefferies’ DeSanctis appeared on a CNBC Television interview to discuss what’s next for small-cap stocks.
Lexicon Pharmaceuticals Inc. (LXRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 44,303,518 | $69,113,488 | +14% | 1.92% |
| 2. | Sessa Capital John Petry | 17,912,961 | $27,944,219 | +498% | 0.51% |
| 3. | Point72 Asset Management Steve Cohen | 7,814,606 | $12,190,785 | +2652% | 0.02% |
| 4. | Millennium Management Israel Englander | 4,944,731 | $7,713,780 | +3% | 0% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,376,304 | $3,707,035 | +89% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.49 | 2,000 | $2,980.00 | 1,906,186 | 2026-02-25 | Filing | |
| $1.47 | 100,000 | $147,000.00 | 1,904,186 | 2026-02-23 | Filing | |
| $1.48 | 100,000 | $147,790.00 | 1,804,186 | 2026-02-20 | Filing | |
| $1.44 | 50,000 | $71,965.00 | 1,704,186 | 2026-02-19 | Filing | |
| $1.32 | 133,688 | $176,468.16 | 1,654,186 | 2026-02-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.93 | 12,000 | $83,100.00 | 71,766 | 2021-03-15 | Filing | |
| $6.90 | 10,912 | $75,339.72 | 71,766 | 2021-03-15 | Filing | |
| $12.91 | 10,000 | $129,076.00 | 25,643 | 2018-06-08 | Filing | |
| $15.00 | 1,500 | $22,500.00 | 15,946 | 2016-06-06 | Filing | |
| $13.00 | 6,000 | $78,000.00 | 15,946 | 2016-05-23 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,139 | $26,949 | 0% | |
| 2. | 1,412 | $3,389 | 0% | |
| 3. | 957 | $2,297 | 0% | |
| 4. | 706 | $1,694 | 0% | |
| 5. | 37 | $89 | 0% |
News See All
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?
Is LXRX a good stock to buy? We came across a bullish thesis on Lexicon Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on LXRX.
10 Best Penny Stocks to Buy for Long Term
The opportunity is not in buying every low-priced penny stock but rather in finding smaller companies where earnings, balance sheets, and business quality are improving faster than the market is giving...
8 Best Fast Growing Penny Stocks to Buy Right Now
On May 4, Gregory Daco, EY-Parthenon Chief Economist, joined CNBC's 'Squawk Box' to discuss the current state of the US economy and the Fed's likely trajectory.
9 Best Biotech Penny Stocks to Buy in 2026
On April 24, Drew Pettit, Citi US equity strategist, joined 'The Exchange' on CNBC to discuss the market fundamentals this year, with a positive outlook for the market as investors look past geopolitical...
10 Best Penny Stocks to Buy and Hold Under $5
Smaller companies have started to attract more attention on Wall Street.
10 High-Flying Penny Stocks to Buy
On March 17, Jim Stoeffel and Andrew Palen, Portfolio Managers at Royce Investment Partners, released a research report discussing how micro-caps can stay on top.
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating
On March 5, 2026, H.C. Wainwright raised the price target on Lexicon Pharmaceuticals, Inc.
11 Fastest Growing Penny Stocks to Buy Right Now
Interest in smaller companies has been quietly building on Wall Street.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript
Operator: Welcome to the Lexicon Pharmaceuticals, Inc. Fourth Quarter and Full Year 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Hedge Fund Resource Center